Lv6
2180 积分 2023-09-16 加入
Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer
2个月前
已完结
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
2个月前
已完结
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
2个月前
已完结
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
2个月前
已完结
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment
2个月前
已完结
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
2个月前
已完结
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
2个月前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
3个月前
已完结
Morphology of Pararectal Lymph Nodes in Rectal Cancer after Neoadjuvant Therapy
3个月前
已完结
Mismatch repair system deficiency is associated with chemoradiotherapy resistance in locally advanced rectal adenocarcinoma patients
3个月前
已完结
皖公网安备34019202002308
